Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03DJT
|
|||
| Former ID |
DIB013439
|
|||
| Drug Name |
Bococizumab
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J44, J44.9] | Phase 3 | [1], [2] | |
| Company |
Pfizer
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Proprotein convertase subtilisin/kexin type 9 (PCSK9) | Target Info | . | [3] |
| WikiPathways | PCSK9-mediated LDLR degradation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7730). | |||
| REF 2 | ClinicalTrials.gov (NCT02458287) Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia. | |||
| REF 3 | The dyslipidaemia market. Nat Rev Drug Discov. 2014 Nov;13(11):807-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.